Drug intelligence / Profile preview

BT-200

Development stage: Preclinical
Lead developer: Biora Therapeutics
Modality: Peptides
Administration: Oral

Overview

**BT-200** is a preclinical Biora Therapeutics drug-device program formerly associated with Progenity for systemic oral delivery of a peptide glucagon-like peptide 1 receptor agonist. The program uses the ingestible BioJet smart capsule, which is designed to protect the peptide during gastrointestinal transit and deploy a needle-free liquid jet into the small intestine for systemic absorption. It is being developed for undisclosed metabolic-disorder indications.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on BT-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT-200.

Explore the full profile